http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
- 中文 을 입력하시려면 zhongwen을 입력하시고 space를누르시면됩니다.
- 北京 을 입력하시려면 beijing을 입력하시고 space를 누르시면 됩니다.
RISS 인기검색어
- 검색키워드
- 저자 : Yan-Rong Gong (검색결과 6 건)
- 무료
- 기관 내 무료
- 유료
-
Simulation Studies on the Structural Stability and Properties of Beta Uranium
Yan-Rong Gong,Tao Gao,Guang-Ai Sun,Ben-Qiong Liu,Bo Chen 한국물리학회 2015 THE JOURNAL OF THE KOREAN PHYSICAL SOCIETY Vol.66 No.2
The structural stability of beta uranium (-U) is investigated by using the projector augmentedwave (PAW) method based on the density function theory (DFT). Optimized lattice parameters arein agreement with other available data. Especially, the energy per atom and the phonon propertiesmanifest that the model described by using space group No. 102 can be stabilized vibrationallyand energetically. A reasonable agreement with the experimental data for the phonon entropycorresponding to the proper structure has been successfully achieved. Moreover, the thermodynamicfunctions are predicated at elevated temperatures.
-
-
The Fingerprinting of Huangjinju Powder for Injection on Chinese Patent Medicine by XRD Fourier
Yan-Li Pan,Gui-Jun Zhang,Ning-Bo Gong,Yun-Shan Wu,Yang Lu,Rong Luo,Ho-Young Choi 韓國藥用作物學會 2006 한국약용작물학회지 Vol.14 No.2
The purpose is to study the identification method of Huangjinju powder for injection and the medicinal materials by the fingerprint off-ray Diffraction Fourier (XRDF). We used the same method on both the studying of Huangjinju and the medicinal materials. Then we selected a few components alignment to compare. We analyzed the data by setting up the deviation d(a) as ±0.05 to calculate the rate of special mark on the sample (Px) and on the patent (P). The special XRDF of Huangjinju[d(a)/(I/I0)] have 5 peaks that have not expressed in medicinal materials. Therefore Px is 22.73%. Flos Trollii Chinensis has 3 special marks and Px is 17.65%. Flos Chrysanthemi Indici has 1 special mark and Px is 3.57%. Its coincided interplanar spacing with the patent is 2.907a. Flos Lonicerae Japonicae has 6 special marks and Px is 23.08%. Its special mark in the patent are 4.95/14 and 4.50/15, respectively. The P is 9.09%. Its coincided interplanar spacing with the patent is 2.910a and 3.05a, respectively. The number of special XRDF mark peaks of baicalin is 9 and Px is 18.37%. Its coincided interplanar spacing with the patent is 2.910a. It has visible mark and specificity adopting XRDF fingerprint to identify Huangjinju and medicinal materials. Establishing the quality standard is a synthetic index that depends both on special marks in the medicinal materials of the patent and on the coincidence peak data.
-
The Fingerprinting of Huangjinju Powder for Injection on Chinese Patent Medicine by XRD Fourier
Pan, Yan-Li,Zhang, Gui-Jun,Gong, Ning-Bo,Wu, Yun-Shan,Lu, Yang,Luo, Rong,Choi, Ho-Young The Korean Society of Medicinal Crop Science 2006 한국약용작물학회지 Vol.14 No.2
The purpose is to study the identification method of Huangjinju powder for injection and the medicinal materials by the fingerprint off-ray Diffraction Fourier (XRDF). We used the same method on both the studying of Huangjinju and the medicinal materials. Then we selected a few components alignment to compare. We analyzed the data by setting up the deviation $d({\AA})$ as ${\pm}0.05$ to calculate the rate of special mark on the sample (Px) and on the patent (P). The special XRDF of Huangjinju$[d({\AA})/(I/I_0)]$ have 5 peaks that have not expressed in medicinal materials. Therefore Px is 22.73%. Flos Trollii Chinensis has 3 special marks and Px is 17.65%. Flos Chrysanthemi Indici has 1 special mark and Px is 3.57%. Its coincided interplanar spacing with the patent is $2.907{\AA}$. Flos Lonicerae Japonicae has 6 special marks and Px is 23.08%. Its special mark in the patent are 4.95/14 and 4.50/15, respectively. The P is 9.09%. Its coincided interplanar spacing with the patent is $2.910{\AA}\;and\;3.05{\AA}$, respectively. The number of special XRDF mark peaks of baicalin is 9 and Px is 18.37%. Its coincided interplanar spacing with the patent is $2.910{\AA}$. It has visible mark and specificity adopting XRDF fingerprint to identify Huangjinju and medicinal materials. Establishing the quality standard is a synthetic index that depends both on special marks in the medicinal materials of the patent and on the coincidence peak data.
-
Lung-Targeting Delivery of Dexamethasone Acetate Loaded Solid Lipid Nanoparticles
Qing-yu Xiang,Yuan Huang,Zhi-rong Zhang,Min-ting Wang,Fu Chen,Tao Gong,Yan-lin Jian 대한약학회 2007 Archives of Pharmacal Research Vol.30 No.4
The objective of the present study was to develop a novel solid lipid nanoparticle (SLN) for the lung-targeting delivery of dexamethasone acetate (DXM) by intravenous administration. DXM loaded SLN colloidal suspensions were prepared by the high pressure homogenization method. The mean particle size, drug loading capacity and drug entrapment efficiency (EE %) of SLNs were investigated. In vitro drug release was also determined. The biodistribution and lung-targeting efficiency of DXM-SLNs and DXM-solutions (DXM-sol) in mice after intravenous administration were studied using reversed-phase high-performance liquid chromatography (HPLC). The results (expressed as mean ± SD) showed that the DXM-SLNs had an average diameter of 552 ± 6.5 nm with a drug loading capacity of 8.79 ± 0.04% and an entrapment efficiency of 92.1 ± 0.41%. The in vitro drug release profile showed that the initial burst release of DXM from DXM-SLNs was about 68% during the first 2 h, and then the remaining drug was released gradually over the following 48 hours. The biodistribution of DXM-SLNs in mice was significantly different from that of DXM-sol. The concentration of DXM in the lung reached a maximum level at 0.5 h post DXM-SLNs injection. A 17.8-fold larger area under the curve of DXM-SLNs was achieved compared to that of DXM-sol. These results indicate that SLN may be promising lung-targeting drug carrier for lipophilic drugs such as DXM.
-
Lung-Targeting Delivery of Dexamethasone Acetalte Loaded Solid Lipid Nanoparticles
Xiang, Qing-Yu,Wang, Min-Ting,Chen, Fu,Gong, Tao,Jian, Yan-Lin,Zhang, Zhi-Rong,Huang, Yuan 대한약학회 2007 Archives of Pharmacal Research Vol.30 No.4
The objective of the present study was to develop a novel solid lipid nanoparticle (SLN) for the lung-targeting delivery of dexamethasone acetate (DXM) by intravenous administration. DXM loaded SLN colloidal suspensions were prepared by the high pressure homogenization method. The mean particle size, drug loading capacity and drug entrapment efficiency (EE %) of SLNs were investigated. In vitro drug release was also determined. The biodistribution and lung-targeting efficiency of DXM-SLNs and DXM-solutions (DXM-sol) in mice after intravenous administration were studied using reversed-phase high-performance liquid chromatography(HPLC). The results (expressed as mean ${\pm}$ SD) showed that the DXM-SLNs had an average diameter of 552 ${\pm}$ 6.5 nm with a drug loading capacity of 8.79 ${\pm}$ 0.04% and an entrapment efficiency of 92.1 ${\pm}$ 0.41%. The in vitro drug release profile showed that the initial burst release of DXM from DXM-SLNs was about 68% during the first 2 h, and then the remaining drug was released gradually over the following 48 hours. The biodistribution of DXM-SLNs in mice was significantly different from that of DXM-sol. The concentration of DXM in the lung reached a maximum level at 0.5 h post DXM-SLNs injection. A 17.8-fold larger area under the curve of DXM-SLNs was achieved compared to that of DXM-sol. These results indicate that SLN may be promising lung-targeting drug carrier for lipophilic drugs such as DXM.
KCI연관 검색어 추천
이 검색어로 많이 본 자료
활용도 높은 자료
